Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

Inclusion Criteria: * Signed, written informed consent. * BRAF V600 mutation-positive tumor: as confirmed by a Clinical Laboratory Improvement Amendments (CLIA) approved local laboratory or equivalent. * Male or female between 18 to 65 years of age, inclusive, at the time of signing the informed consent form; * Capable of compliance with the requirements and restrictions listed in the consent form; * Body weight \>= 45 kilogram (kg) and a body mass index \>= 19 kilogram per squaremeter (kg/m\^2)and \<40 kg/m\^2 (inclusive); * Able to swallow and retain orally administered medication * Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1. NOTE: Subjects with a performance status of 2 can be enrolled if the subject's confinement to bed and inability to carry out work activities is due solely to cancer-related pain, as assessed by the Investigator. * Adequate baseline organ function defined as: absolute neutrophil count \>= 1.2 x 10\^9/Liter (L); hemoglobin\>=9 gram per deciliter (g/dL); platelets \>= 75 x 10\^9/L; prothrombin time /international normalized ratio and partial thromboplastin time =\<1.3 x ULN; serum bilirubin=\<1.5 times upper limit of normal (ULN); aspartate aminotransferase and alanine aminotransferase =\<2.5 times ULN; serum creatinine=\<1.5 mg/dL or calculate creatinine clearance \>= 50 milliliter per minute; Left ventricular ejection fraction\>= lower limit of normal by echocardiography. * Women of child-bearing potential must be willing to p…